Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › basiliximab

basiliximab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of basiliximab

19 trials tracked of basiliximab: 13 in phase 3 or 4 and 1 with published results. The most-cited published study has 148 citations.

19Trials tracked
13Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 7 Phase 3 6 Phase 2 6
  1. Phase 3 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Completed · 148 cited
  2. Phase 4 Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation Completed
  3. Phase 4 A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients Completed
  4. Phase 4 Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients Completed
  5. Phase 4 Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients Completed
  6. Phase 4 Steroid Free Immunosuppression in Liver Transplantation Completed
Show 13 more trials
  1. Phase 4 Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients Completed
  2. Phase 4 Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients Completed
  3. Phase 3 A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients Completed
  4. Phase 3 Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids Completed
  5. Phase 3 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy Completed
  6. Phase 3 Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients Completed
  7. Phase 3 Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids Completed
  8. Phase 2 Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients Completed
  9. Phase 2 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed
  10. Phase 2 Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant Completed
  11. Phase 2 Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Completed
  12. Phase 2 DC Migration Study for Newly-Diagnosed GBM Completed
  13. Phase 2 A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation
Orthopedics & Sports Medicine Guideline
Scoping review synthesizes immunosuppressive strategies and outcomes in solid organ transplantation New Drug Strategies Aim to Stop Your Body From Rejecting a Transplant
This scoping review examines immunosuppressive strategies for solid organ transplant patients, including conventional, biologic, and emergin…
New drug strategies aim to stop your body from attacking a new organ, protecting transplants longer while reducing dangerous side effects fr…
Frontiers Apr 20, 2026